Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.44 |
| ▸ | F11 | P03951 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3263222 | 1.00 | LPL (0.47) | LPLLIPGLTA4HHRH3F11 | |
| SCHEMBL3263221 | 1.00 | LPL (0.47) | LPLLIPGLTA4HHRH3F11 | |
| SCHEMBL3261155 | 0.94 | HRH3 (0.44) | LPLLIPGLTA4HHRH3F11 | |
| SCHEMBL3260869 | 0.92 | LPL (0.49) | LPLLIPGLTA4HHRH3F11 | |
| SCHEMBL21055138 | 0.90 | LPL (0.50) | LPLLIPGHRH3F11ESR2 | |
| SCHEMBL18580257 | 0.88 | LPL (0.46) | LPLLIPGLTA4HHRH3F11 | |
| SCHEMBL3262791 | 0.85 | ALDH1A1 (0.46) | LPLLIPGLTA4HF11ESR2 | |
| SCHEMBL3261633 | 0.85 | ALDH1A1 (0.46) | LPLLIPGLTA4HF11ESR2 | |
| SCHEMBL3261628 | 0.85 | ALDH1A1 (0.46) | LPLLIPGLTA4HF11ESR2 | |
| SCHEMBL18580899 | 0.85 | LPL (0.48) | LPLLIPGLTA4HHRH3F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320228-A1 | PYRIDO[3,2-D]PYRIMIDINES AS HPK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2025-10-16 | — | — | US | disclosed |
| EP-4507789-A1 | PYRIDO[3,2-D]PYRIMIDINES AS HPK1 INHIBITORS | Merck Patent GmbH (DE) | 2025-02-19 | — | — | EP | disclosed |
| WO-2023201185-A1 | PYRIDO[3,2-D]PYRIMIDINES AS HPK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2023-10-19 | — | — | WO | disclosed |
| WO-2010010184-A1 | [1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320228-A1 | PYRIDO[3,2-D]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, PPIP5K2, IP6K1 | LPL 4185/4885LIPG 4471/4885LTA4H 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.